drugset / Trial / NCT04522908
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Phase 2
Completed
40 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Johann Wolfgang Goethe University Hospital, Prof. Dr. med. Trojan · collab
NaSingle-groupOpen-labelTreatment
Summary
Open-label, single arm, multicenter phase II trial assessing the tolerability of a reduced starting dose of 40 mg cabozantinib for 4 weeks and subsequent dose escalation to 60 mg cabozantinib until disease progression or intolerable toxicities.
Timeline
- Start
- 2020-10-12
- Primary completion
- 2024-10-04
- Completion
- 2024-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |